AXA/2026/1Q activity indicators press release: Difference between revisions
Content deleted Content added
PlumBot: publish from draft |
PlumBot: publish from draft |
||
Line 18:
== 1Q26 highlights ==
* Gross written premiums & other revenues (footnote: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities).) '''+6%''' vs. 1Q25 to '''EUR 38.0bn''' <sup>p. 1</sup>
** Property & Casualty premiums '''+4%''' to '''EUR 21.5bn''' <sup>p. 1</sup>
*** Retail premiums '''+7%''' (+4% from price effect, +3% from volumes) <sup>p. 1</sup>
Line 25:
*** Life premiums '''+8%''' <sup>p. 1</sup>
*** Health premiums '''+8%''' <sup>p. 1</sup>
* Life & Health NB CSM (footnote: a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided.) '''+4%''' <sup>p. 1</sup>
* Net flows (footnote: Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) '''+EUR 2.7bn''' <sup>p. 1</sup>
* Solvency II ratio (footnote: estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of Euro 2.32 per share to be paid in 2026 for FY25 and annual share buyback of Euro 1.25 billion announced on February 26, 2026. Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stockbased compensation. Dividend s and share buybacks are proposed by the Board, at its discretion based on a variety of factors described in AXA's 202 5 Universal Registration Document and then submitted to AXA's shareholders for approval. This estimate should not be considered in any way to be an indication of the actual dividend and share buyback amounts, if any, for the 2026 financial year. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com).) '''211%''' as of March 31, 2026 <sup>p. 1</sup>
**
== Outlook 3 ==
Line 33 ⟶ 34:
* AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the '''6-8%''' plan target range <sup>p. 1</sup>
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup>
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>▼
<blockquote>"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy. This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
<blockquote>"In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
<blockquote>"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
Line 55 ⟶ 41:
* The press release was issued in Paris on May 5, 2026, at 5:45pm CET <sup>p. 1</sup>
* The document covers 1Q26 Activity indicators,
* All footnotes for this press release are on page 7 <sup>p. 1</sup>
Line 62 ⟶ 48:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 97 ⟶ 83:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | FY25
Line 117 ⟶ 103:
** Property & Casualty '''+4%''' <sup>p. 2</sup>
*** Personal lines '''+7%''' (driven by higher volumes and favorable price effect) <sup>p. 2</sup>
*** Commercial lines (footnote: P&C Commercial lines excluding AXA XL Reinsurance.) '''+3%''' (from higher volumes, notably at AXA XL Insurance, and favorable price effect mainly in SME & Mid-market business in Europe and France) <sup>p. 2</sup>
*** AXA XL Reinsurance '''-7%''' (reflecting discipline in softening market conditions) <sup>p. 2</sup>
** Life & Health '''+8%''' <sup>p. 2</sup>
*** Life premiums '''+8%''' (driven by strong sales in Unit-Linked (+16%)
*** Health premiums '''+8%''' (driven by favorable price effects across all geographies) <sup>p. 2</sup>
* Solvency II ratio was '''211%''' as of March 31, 2026 <sup>p. 2</sup>
** On January 1, 2026, the Solvency II ratio was '''215%''' following the end of the grandfathering period (footnote: Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, at which point they ceased to qualify as capital under Solvency II, as disclosed in AXA's respective press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings, each published on www.axa.com.) (-10 points vs. December 31, 2025) <sup>p. 2</sup>
*
***
***
== Property & Casualty ==
Line 133 ⟶ 118:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Property & Casualty:
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 166 ⟶ 151:
</div>
* Gross written premiums & other revenues for
* Personal lines grew by '''
** Europe
** France
** Asia, Africa & EME LATAM
* Commercial lines grew by '''
** AXA XL Insurance
**
**
**
**
* Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup>
* The annual natural catastrophe (footnote: Natural catastrophe charges include natural catastrophe losses regardless of event size.) budget of ca. '''4.5 points''' of combined ratio (footnote: a nonGAAP financial measure, or alternative performance measure ('APM'). Please see the paragraph 'Important legal information and cautionary statements concerning forward-looking statements and the use of nonGAAP financial measures' i n this press release for important information about APMs used by AXA.) is maintained <sup>p. 3</sup>
== Life & Health ==
Line 185 ⟶ 170:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Life & Health:
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 242 ⟶ 227:
</div>
*
* All year-on-year changes are on a comparable basis versus the updated 1Q25 figures <sup>p. 4</sup>
* Gross written premiums & other revenues for Life & Health were '''+8%''' to '''EUR 16.5bn''' <sup>p. 4</sup>
* Life premiums increased by '''
** Unit-Linked
** G/A Savings
** Protection
* Health premiums increased by '''
*
** Life
** Health
* NB CSM (pre-tax)
** Driven by strong Savings and Protection sales across most geographies <sup>p. 4</sup>
* NBV (post-tax) '''+1%''' to '''EUR 0.6bn''', as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup>▼
** Partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan <sup>p. 4</sup>
* NBV (post-tax) (footnote: the value of newly issued contracts during the current year. It consists of the sum of (i) the NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals, and (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests.) '''+1%''' to '''EUR 0.6bn''' <sup>p. 4</sup>
* Net flows were '''EUR +2.7bn''', compared to '''EUR +2.5bn''' in 1Q25, driven by: <sup>p. 4</sup>▼
▲*
* NBV margin (footnote: the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP.) decreased by '''0.3 point''' to '''4.4%''' <sup>p. 4</sup>
▲* Net flows were '''EUR +2.7bn'''
** Protection ('''EUR +1.8bn'''), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product <sup>p. 4</sup>
** Unit-Linked ('''EUR +0.7bn'''), primarily in France <sup>p. 4</sup>
** G/A Savings ('''EUR -0.8bn'''), reflecting inflows in capital-light G/A savings ('''EUR +0.7bn'''), more than offset by outflows in traditional G/A Savings ('''EUR -1.5bn''') <sup>p. 4</sup>
** Health ('''EUR +1.0bn'''), mostly from Germany, France
== Ratings ==
Line 266 ⟶ 254:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Insurer
! style="text-align:left" | —
! style="text-align:right; width:9em" | —
Line 299 ⟶ 287:
== Glossary ==
* '''Capital-light G/A products''': encompass all products with no guarantees, with guarantees at maturity only
* '''Contractual service margin ('CSM')''': a component of the carrying amount of
* '''Gross written premiums and other revenues''': insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) <sup>p. 5</sup>
* '''New business contractual service margin ('NB CSM')''': a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 5</sup>
* '''New business
* '''New business value margin ('NBV Margin')''': the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP <sup>p. 5</sup>
▲* '''Present value of expected premiums ('PVEP')''': the new business volume, equal to the present value at the time of issue of total premiums expected to be received over the policy term <sup>p. 5</sup>
▲* '''AMF''': Autorité des marchés financiers
* '''APM''': Alternative Performance Measure
* '''CLP''': Credit and Lifestyle Protection
Line 316 ⟶ 301:
* '''DJSI''': Dow Jones Sustainability Index
* '''DPF''': Discretionary Participation Features
* '''EME''': Emerging Markets Europe
* '''ESMA''': European Securities and Markets Authority
Line 322 ⟶ 306:
* '''GWP''': Gross Written Premiums
* '''IFRS''': International Financial Reporting Standards
▲* '''II''': Solvency II
* '''LFL''': Like-for-Like
* '''NB CSM''': New Business Contractual Service Margin
Line 330 ⟶ 313:
* '''SFCR''': Solvency and Financial Condition Report
* '''SME''': Small and Medium-sized Enterprises
* '''SRI''': Socially Responsible
* '''UEPS''': Underlying Earnings Per Share
* '''UN''': United Nations
Line 336 ⟶ 319:
== Scope ==
* '''France''': includes insurance activities, banking activities
* '''Europe''': includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and
* '''AXA XL''': includes insurance and reinsurance activities and holding <sup>p. 6</sup>
* '''Asia, Africa & EME-LATAM''': <sup>p. 6</sup>
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (
** '''Asia (equity method)''': China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (the bancassurance entity)
** '''Africa''': Egypt (insurance activities and holding), Morocco (insurance activities and holding)
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding)
** '''EME-LATAM (equity method)''': Russia (Reso) (insurance activities)
**
* '''Transversal & Other''': includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (
* '''AXA Investment Managers''': disposal to BNP Paribas completed on July 1, 2025 <sup>p. 6</sup>
Line 353 ⟶ 336:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ End of
! style="text-align:left" | —
! colspan="2" style="text-align:center" | End of Period Exchange rate
Line 392 ⟶ 375:
== Notes ==
*
* These and other terms are defined in the glossary section of this press release <sup>p. 7</sup>
* The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock <sup>p. 7</sup>
*
* Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation <sup>p. 7</sup>
* Dividends and share buybacks are proposed by the Board, at its discretion
* This estimate should not be considered an indication of the actual dividend and share buyback amounts for the 2026 financial year <sup>p. 7</sup>
* For further information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on
* Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement to provide one-off guidance
* This
* 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance <sup>p. 7</sup>
* Price effect is calculated as a percentage of total gross written premiums of the prior year <sup>p. 7</sup>
* General account (G/A
* Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026,
* This was disclosed in AXA's press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings
▲* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>
* Combined ratio is a non-GAAP financial measure, or alternative performance measure ('APM') <sup>p. 7</sup>
* Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities <sup>p. 7</sup>
* Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's <sup>p. 7</sup>
* Tier 2 is rated 'A' by Standard & Poor's and '
* AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 <sup>p. 7</sup>
* All comments and changes
* Actuarial and financial assumptions used for the calculation of NBV and PVEP are updated semi-annually at half year and full year <sup>p. 7</sup>
* Financial figures and information in this press release have not been audited and have not been subject to any limited review by AXA's statutory auditors <sup>p. 7</sup>
Line 422 ⟶ 402:
== About the AXA Group ==
* AXA Group is a worldwide leader in insurance with '''156,000
* In 2025, AXA's revenues were '''EUR 115.5bn''' and underlying earnings were '''EUR 8.4bn''' <sup>p. 8</sup>.
* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol '''CS''' (ISN '''FR 0000120628'''; Bloomberg: '''CS FP'''; Reuters: '''AXAF.PA''') <sup>p. 8</sup>.
* AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol '''AXAHY''' <sup>p. 8</sup>.
* AXA Group is included in main international SRI indexes,
* AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment <sup>p. 8</sup>.
*
* Forward-looking statements in
* Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially <sup>p. 8</sup>.
* AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations <sup>p. 8</sup>.
*
* Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Group's consolidated financial statements prepared in accordance with IFRS <sup>p. 8</sup>.
*
* Reconciliations of APMs to financial statements are provided in the 2025 Universal Registration Document, Section 2.3.3 'Alternative Performance Measures' <sup>p. 8</sup>.
*
*
*
▲* Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com <sup>p. 8</sup>.
* Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments <sup>p. 8</sup>.
* SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes <sup>p. 8</sup>.
Line 448 ⟶ 424:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+
! style="text-align:left" | EUR million
! colspan="5" style="text-align:center" | GWP & Other Revenues
Line 544 ⟶ 520:
</div>
* Banking revenues
* Portfolio of lifestyle and income protection (CLP) premiums reallocated from France to Transversal
***
***
* International protection and health premiums previously recorded in AXA France are now reported under the new carrier AXA Health International, which is part of Europe <sup>p. 9</sup>.
***
***
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+
! style="text-align:left" | EUR million
! colspan="2" style="text-align:center" | Commercial lines
Line 666 ⟶ 642:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+
! style="text-align:left" | —
! style="text-align:right; width:6em" | FY25 i
Line 699 ⟶ 675:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ P&C
! style="text-align:left" | 1Q26 (in %)
! style="text-align:right; width:6em" | Commercial lines
Line 761 ⟶ 737:
|}
</div>
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Life & Health
! style="text-align:left" | EUR million
! colspan="2" style="text-align:center" | Total i
Line 876 ⟶ 850:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q25
! style="text-align:left" | EUR million
! colspan="4" style="text-align:center" | Life
Line 970 ⟶ 944:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1H25
! style="text-align:left" | EUR million
! colspan="4" style="text-align:center" | Life
Line 1,064 ⟶ 1,038:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 9M25
! style="text-align:left" | EUR million
! style="text-align:right; width:6em" | PVEP
Line 1,153 ⟶ 1,127:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q25
! style="text-align:left" | EUR million
! style="text-align:
! style="text-align:
! style="text-align:
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,192 ⟶ 1,157:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1H25
! style="text-align:left" | EUR million
! style="text-align:
! style="text-align:
! style="text-align:
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,231 ⟶ 1,187:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 9M25
! style="text-align:left" | EUR million
! style="text-align:
! style="text-align:
! style="text-align:
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,272 ⟶ 1,219:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26
! style="text-align:left" | EUR million
! colspan="8" style="text-align:center" | Life New Business Metrics 1Q26
Line 1,438 ⟶ 1,385:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ NB CSM to NBV
! style="text-align:left" | EUR million
! style="text-align:right; width:6em" | Life
Line 1,466 ⟶ 1,413:
</div>
*
* Changes are
=== Net flows by business line ===
Line 1,473 ⟶ 1,420:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Net
! style="text-align:left" | EUR billion
! style="text-align:right; width:6em" | 1Q25
Line 1,508 ⟶ 1,455:
</div>
*
* Capital light G/A encompasses all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 15</sup>.
*
* A share repurchase agreement for up to '''EUR 1.25bn''' was announced on February 27, 2026 <sup>p. 16</sup>.
* Next main investor events:
*** HY26 Earnings Release on July 31, 2026 <sup>p. 16</sup>.
*** AXA Investor Day on September 15, 2026 <sup>p. 16</sup>.
*** AXA Investor roundtable on the strategy for AXA key markets on September 21, 2026 <sup>p. 16</sup>.
*** 9M26 Activity Indicators on October 29, 2026 <sup>p. 16</sup>.
| |||